↑ 疾患リストへ ← 戻る

 167. マルファン症候群 [臨床試験数:14,薬物数:28(DrugBank:10),標的遺伝子数:10,標的パスウェイ数:45] 

Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-023612-14-GB08/03/201318 March 2013The Oxford Marfan TrialA randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0Marfan syndrome.
MedDRA version: 14.1 Level: PT Classification code 10026829 Term: Marfan's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Aprovel
Product Name: Aprovel
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Irbesartan
CAS Number: 38402-11-6
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 150-300
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Trade Name: Vibrox 100mg Capsules
Product Name: Vibrox
Pharmaceutical Form: Capsule
INN or Proposed INN: Doxycycline Hyclate Ph.Eur
CAS Number: 564-25-0
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 100-200
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Clinical Trials and Research GovernanceAuthorisedFemale: yes
Male: yes
United Kingdom
2EUCTR2010-019302-16-GB13/09/201028 February 2019A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndromeA prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome - The AIMS StudyMarfan SyndromeTrade Name: Aprovel
Product Name: Aprovel
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
Royal Brompton and Harefield NHS Foundation TrustNot Recruiting Female: yes
Male: yes
490Phase 3United Kingdom
3NCT01715207June 201016 December 2017Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFSComparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With AtenololMarfan SyndromeDrug: Aliskiren;Drug: AtenololSamsung Medical CenterNot recruiting14 Years55 YearsAll30Phase 3Korea, Republic of
4NCT00782327June 200929 June 2015Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockersRandomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockersMarfan SyndromeDrug: Losartan;Drug: PlaceboUniversity Hospital, GhentAgentschap voor Innovatie door Wetenschap en TechnologieRecruiting10 YearsN/ABoth174Phase 3Belgium
5EUCTR2007-005862-10-BE29/05/200910 July 2015Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers.Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers.Marfan syndrome
MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome
Trade Name: Cozaar
Product Name: Losartan
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Losartan potassium
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Coozar
Product Name: Losartan
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Losartan potassium
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Coozar
Product Name: Losartan
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Losartan potassium
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
University Hospital GhentNot RecruitingFemale: yes
Male: yes
Belgium
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2008-001462-81-IT27/10/20089 May 2016Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - NDEffects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - NDMarfan Syndrome
MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome
Trade Name: LORTAAN*28CPR RIV DIV 50MG
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Losartan
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Trade Name: LOBIVON*28CPR 5MG
Pharmaceutical Form: Tablet
INN or Proposed INN: Nebivolol
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
OSPEDALE POLICLINICO S. MATTEONot RecruitingFemale: yes
Male: yes
Phase 3Italy
7EUCTR2007-001125-97-ES20/05/200819 March 2012Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome)Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome)The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol
MedDRA version: 9.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome
Trade Name: cozaar 50
Pharmaceutical Form: Capsule*
INN or Proposed INN: LOSARTAN POTASSIUM
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Trade Name: blokium 50
Pharmaceutical Form: Capsule*
INN or Proposed INN: ATENOLOL
CAS Number: 29122687
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula
Pharmaceutical Form: Capsule*
INN or Proposed INN: LOSARTAN POTASSIUM
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Trade Name: BLOKIUM 50 mg comprimidos
Pharmaceutical Form: Capsule*
INN or Proposed INN: ATENOLOL
CAS Number: 29122687
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
alberto fortezaAuthorisedFemale: yes
Male: yes
Spain
8NCT00593710January 200819 February 2015Losartan Versus Atenolol for the Treatment of Marfan SyndromeA Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan SyndromeMarfan SyndromeDrug: Losartan;Drug: AtenololUniversity of British ColumbiaHeart and Stroke Foundation of CanadaNot recruiting12 Years25 YearsBoth17Phase 2Canada
9NCT00723801October 200719 October 2017Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan SyndromeEffects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan SyndromeMarfan SyndromeDrug: Atenolol;Drug: LosartanBrigham and Women's HospitalBoston Children’s HospitalNot recruiting25 YearsN/AAll40Phase 3United States
10NCT00651235February 200719 February 2015A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan SyndromeA Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan SyndromeMarfan SyndromeDrug: Losartan and Atenolol or Propranolol;Drug: Atenolol or PropranololNational Taiwan University HospitalRecruiting1 YearN/ABoth44Phase 2Taiwan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00429364January 200719 October 2017Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart NetworkTrial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)Marfan SyndromeDrug: Losartan Potassium;Drug: AtenololNew England Research InstitutesNational Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan FoundationNot recruiting6 Months25 YearsAll608Phase 3United States;Belgium;Canada
12EUCTR2006-003991-37-BE13/12/200611 April 2016Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan TrialTrial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan TrialMarfan syndrome
MedDRA version: 8.1 Level: LLT Classification code 10026829 Term: Marfan's syndrome
Product Name: losartan
Pharmaceutical Form: Tablet
INN or Proposed INN: Losartan potassium
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
Product Name: losartan
Pharmaceutical Form: Tablet
INN or Proposed INN: Losartan potassium
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Product Name: losartan
Pharmaceutical Form: Tablet
INN or Proposed INN: Losartan potassium
CAS Number: 124750998
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Product Name: Atenolol
Pharmaceutical Form: Tablet
INN or Proposed INN: Atenolol
CAS Number: 29122687
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Product Name: Atenolol
Pharmaceutical Form: Tablet
INN or Proposed INN: Atenolol
CAS Number: 29122687
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Product Name: Atenolol
Pharmaceutical Form: Tablet
INN or Proposed INN: Atenolol
CAS Number: 29122687
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
University Hospital GentNot RecruitingFemale: yes
Male: yes
600Belgium
13EUCTR2005-000749-13-GB30/07/200524 April 2012A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome.A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome.Marfan SyndromeTrade Name: Atenolol
Product Name: Atenolol
Product Code: N/A
Pharmaceutical Form: Capsule*
INN or Proposed INN: N/A
CAS Number: -29122-68-7
Current Sponsor code: CO7AB03
Other descriptive name: N/A
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75 MG ONCE DAILY-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Coversyl
Product Name: Coversyl
Product Code: N/A
Pharmaceutical Form: Capsule*
INN or Proposed INN: N/A
CAS Number: -95153-31-4
Current Sponsor code: CO9AA04
Other descriptive name: PERINDOPRIL
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4MG ONCE DAILY
Route of administration of the placebo: Oral use
Trade Name: Verapamil
Product Code: N/A
Pharmaceutical Form: Capsule*
INN or Proposed INN: N/A
CAS Number: -152-11-4
Current Sponsor code: CO8DA01
Other descriptive name: N/A
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 240 MG ONCE DAILY-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Cardiff UniversityAuthorisedFemale: yes
Male: yes
60United Kingdom
14NCT00485368January 200419 February 2015Angiotensin Converting Enzyme Inhibitors in Marfan SyndromeThe Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.Marfan SyndromeDrug: Coversyl (perindopril)Bayside HealthBaker Heart Research Institute;The AlfredNot recruiting18 Years40 YearsBoth17Phase 3

先頭へ